China Archives - Page 2 of 5 -

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact

Nine for 2021: Addressing the pandemic legacy

https://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/

Coronavirus vaccine: how pharma is picking up the pace

News/ News/ R&D

Sanofi preps trials of second COVID-19 shot, as Russia approves another

Phil Taylor China, coronavirus, coronavirus vaccine, COVID-19, Russia, Sanofi, Translate Bio 0 Comment

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after

Sanofi preps trials of second COVID-19 shot, as Russia approves another

https://pharmaphorum.com/news/sanofi-preps-trials-of-second-covid-19-shot-as-russia-approves-another/

News/ News/ Patients

China starts vaccinating key workers against COVID-19; report

Phil Taylor China, coronavirus, coronavirus vaccine, COVID-19 0 Comment

China has already granted emergency use authorisation to multiple COVID-19 vaccines developed by domestic drugmakers and started dosing

China starts vaccinating key workers against COVID-19; report

https://pharmaphorum.com/news/chinese-starts-vaccinating-key-workers-against-covid-19-report/

News/ News/ Sales and Marketing

Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact

Phil Taylor Bayer, China, coronavirus, COVID-19, Eylea, litigation, Xarelto 0 Comment

Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion

Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact

https://pharmaphorum.com/news/bayer-slides-on-e9-5bn-loss-caused-by-litigation-covid-19-impact/

Digital/ News/ News

BI opens second branch of digital lab in China

Richard Staines AstraZeneca, Boehringer Ingelheim, China, digital health, Merck KGaA, R&D 0 Comment

Boehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in

BI opens second branch of digital lab in China

https://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/

Market Access/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Does pharma’s future lie in China?

mike.hammerton@pharmaphorum.com China 0 Comment

Healthcare innovation has a long history in effective collaboration, whether that’s across academia and industry or borders. Some

Does pharma’s future lie in China?

https://pharmaphorum.com/r-d/views-analysis-r-d/does-pharmas-future-lie-in-china/

News

Vifor forges iron drug partnership with Fresenius in China

Richard Staines China, Fresenius Kabi, iron deficiency, market access, Vifor Pharma 0 Comment

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency

Vifor forges iron drug partnership with Fresenius in China

https://pharmaphorum.com/news/vifor-forges-iron-drug-partnership-with-fresenius-in-china/

Digital/ Market Access/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Nine pharma trends for 2020

mike.hammerton@pharmaphorum.com biosimilars, China, genomic medicine, genomics, RWE 0 Comment

Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for

Nine pharma trends for 2020

https://pharmaphorum.com/views-analysis-digital/nine-pharma-trends-for-2020/

News/ News/ News/ Oncology/ R&D

China’s Adagene raises $69m for cancer immunotherapies

Phil Taylor Adagene, antibody, China, financing, immuno-oncology, Oncology 0 Comment

Chinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including

China’s Adagene raises $69m for cancer immunotherapies

https://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/

Trending

China

Login